{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:29:04Z","timestamp":1781663344215,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81402116"],"award-info":[{"award-number":["81402116"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072817"],"award-info":[{"award-number":["82072817"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Guangdong Province, China","award":["2019A1515010285"],"award-info":[{"award-number":["2019A1515010285"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03400-z","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T19:18:26Z","timestamp":1710271106000},"page":"1759-1767","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bladder-sparing treatment using tislelizumab combined with gemcitabine\/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study"],"prefix":"10.1007","volume":"26","author":[{"given":"Cheng","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wumier","family":"Wusimanjiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongren","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaihui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4511-9892","authenticated-orcid":false,"given":"Bin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"3400_CR1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859\u201366.","journal-title":"N Engl J Med"},{"key":"3400_CR2","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068\u201377.","journal-title":"J Clin Oncol"},{"key":"3400_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.eururo.2008.07.018","volume":"55","author":"SM Donat","year":"2009","unstructured":"Donat SM, Shabsigh A, Savage C, Cronin AM, Bochner BH, Dalbagni G, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol. 2009;55:177\u201385.","journal-title":"Eur Urol"},{"key":"3400_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2008.07.031","volume":"55","author":"A Shabsigh","year":"2009","unstructured":"Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009;55:164\u201374.","journal-title":"Eur Urol"},{"key":"3400_CR5","doi-asserted-by":"publisher","first-page":"952","DOI":"10.6004\/jnccn.2013.0116","volume":"11","author":"RC Chen","year":"2013","unstructured":"Chen RC, Shipley WU, Efstathiou JA, Zietman AL. Trimodality bladder preservation therapy for muscle-invasive bladder cancer. J Natl Compr Canc Netw. 2013;11:952\u201360.","journal-title":"J Natl Compr Canc Netw"},{"key":"3400_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108111","volume":"236","author":"DR Principe","year":"2022","unstructured":"Principe DR, Kamath SD, Korc M, Munshi HG. The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. Pharmacol Ther. 2022;236: 108111.","journal-title":"Pharmacol Ther"},{"key":"3400_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/cancers14010038","volume":"14","author":"JW van Hattum","year":"2021","unstructured":"van Hattum JW, de Ruiter BM, Oddens JR, Hulshof M, de Reijke TM, Bins AD. Bladder-sparing chemoradiotherapy combined with immune checkpoint inhibition for locally advanced urothelial bladder cancer-a review. Cancers (Basel). 2021;14:38.","journal-title":"Cancers (Basel)"},{"key":"3400_CR8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312\u201322.","journal-title":"Lancet Oncol"},{"key":"3400_CR9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.4143\/crt.2022.343","volume":"55","author":"H Kim","year":"2023","unstructured":"Kim H, Jeong BC, Hong J, Kwon GY, Kim CK, Park W, et al. Neoadjuvant nivolumab plus gemcitabine\/cisplatin chemotherapy in muscle-invasive urothelial carcinoma of the bladder. Cancer Res Treat. 2023;55:636\u201342.","journal-title":"Cancer Res Treat"},{"key":"3400_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1200\/JCO.2020.38.6_suppl.439","volume":"38","author":"S Gupta","year":"2020","unstructured":"Gupta S, Sonpavde G, Weight CJ, McGregor BA, Gupta S, Maughan BL, et al. Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. J Clin Oncol. 2020;38:439.","journal-title":"J Clin Oncol"},{"key":"3400_CR11","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar AV, Castellano D, O\u2019Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483\u201392.","journal-title":"Lancet Oncol"},{"key":"3400_CR12","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1200\/JCO.2021.39.15_suppl.4504","volume":"39","author":"AV Balar","year":"2021","unstructured":"Balar AV, Matthew I, Milowsky MI, O\u2019Donnell PH, Alva AS, Marisa Kollmeier M, et al. Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): a multicenter phase 2 trial. J Clin Oncol. 2021;39:4504.","journal-title":"J Clin Oncol"},{"key":"3400_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1200\/JCO.2020.38.6_suppl.485","volume":"38","author":"AJ Weickhardt","year":"2020","unstructured":"Weickhardt AJ, Foroudi F, Lawrentschuk N, Galleta L, Seegum A, Herschtal A, et al. Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: a planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502). J Clin Oncol. 2020;38:485.","journal-title":"J Clin Oncol"},{"key":"3400_CR14","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1158\/1078-0432.CCR-19-3561","volume":"26","author":"J Xu","year":"2020","unstructured":"Xu J, Bai Y, Xu N, Li E, Wang B, Wang J, et al. Tislelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma and gastric\/gastroesophageal junction adenocarcinoma. Clin Cancer Res. 2020;26:4542\u201350.","journal-title":"Clin Cancer Res"},{"key":"3400_CR15","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","volume":"7","author":"J Wang","year":"2021","unstructured":"Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7:709\u201317.","journal-title":"JAMA Oncol"},{"key":"3400_CR16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/cas.14681","volume":"112","author":"D Ye","year":"2021","unstructured":"Ye D, Liu J, Zhou A, Zou Q, Li H, Fu C, et al. Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Sci. 2021;112:305\u201313.","journal-title":"Cancer Sci"},{"key":"3400_CR17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3233\/BLC-160076","volume":"2","author":"CM Russell","year":"2016","unstructured":"Russell CM, Lebastchi AH, Borza T, Spratt DE, Morgan TM. The role of transurethral resection in trimodal therapy for muscle-invasive bladder cancer. Bladder Cancer. 2016;2:381\u201394.","journal-title":"Bladder Cancer"},{"key":"3400_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.euros.2022.02.010","volume":"39","author":"B-M de Ruiter","year":"2022","unstructured":"de Ruiter B-M, van de Kamp MW, van Steenbergen JPZ, Franckena M, Boormans JL, de Feijter JM, et al. A multicenter retrospective cohort series of muscle-invasive bladder cancer patients treated with definitive concurrent chemoradiotherapy in daily practice. Eur Urol Open Sci. 2022;39:7\u201313.","journal-title":"Eur Urol Open Sci"},{"key":"3400_CR19","doi-asserted-by":"publisher","first-page":"722","DOI":"10.5858\/arpa.2017-0555-OA","volume":"143","author":"M Zajac","year":"2019","unstructured":"Zajac M, Boothman AM, Ben Y, Gupta A, Jin X, Mistry A, et al. Analytical validation and clinical utility of an immunohistochemical programmed death ligand-1 diagnostic assay and combined tumor and immune cell scoring algorithm for durvalumab in urothelial carcinoma. Arch Pathol Lab Med. 2019;143:722\u201331.","journal-title":"Arch Pathol Lab Med"},{"key":"3400_CR20","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reynies A, Allory Y, Sjodahl G, Robertson AG, Seiler R, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77:420\u201333.","journal-title":"Eur Urol"},{"key":"3400_CR21","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/jnci\/djx243","volume":"110","author":"Q Mo","year":"2018","unstructured":"Mo Q, Nikolos F, Chen F, Tramel Z, Lee YC, Hayashi K, et al. Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas. J Natl Cancer Inst. 2018;110:448\u201359.","journal-title":"J Natl Cancer Inst"},{"key":"3400_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.eururo.2012.10.008","volume":"63","author":"DE Hansel","year":"2013","unstructured":"Hansel DE, Amin MB, Comperat E, Cote RJ, Knuchel R, Montironi R, et al. A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur Urol. 2013;63:321\u201332.","journal-title":"Eur Urol"},{"key":"3400_CR23","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s00345-018-2544-8","volume":"37","author":"J Schardt","year":"2019","unstructured":"Schardt J, Roth B, Seiler R. Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when? World J Urol. 2019;37:1759\u201365.","journal-title":"World J Urol"},{"key":"3400_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67\u201376.","journal-title":"Lancet"},{"key":"3400_CR25","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/JCO.21.01485","volume":"40","author":"SA Funt","year":"2022","unstructured":"Funt SA, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo MY, et al. Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial. J Clin Oncol. 2022;40:1312\u201322.","journal-title":"J Clin Oncol"},{"key":"3400_CR26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comperat EM, Cowan NC, Gakis G, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79:82\u2013104.","journal-title":"Eur Urol"},{"key":"3400_CR27","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","volume":"71","author":"NJ Giacalone","year":"2017","unstructured":"Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. Eur Urol. 2017;71:952\u201360.","journal-title":"Eur Urol"},{"key":"3400_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/JCO.18.00537","volume":"37","author":"JJ Coen","year":"2019","unstructured":"Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, et al. Bladder preservation with twice-a-day radiation plus fluorouracil\/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG\/RTOG 0712-a randomized phase II trial. J Clin Oncol. 2019;37:44\u201351.","journal-title":"J Clin Oncol"},{"key":"3400_CR29","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/S0360-3016(03)00763-6","volume":"57","author":"O Caffo","year":"2003","unstructured":"Caffo O, Fellin G, Graffer U, Valduga F, Bolner A, Luciani L, et al. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. Int J Radiat Oncol Biol Phys. 2003;57:1310\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3400_CR30","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.ijrobp.2004.05.074","volume":"61","author":"VK Sangar","year":"2005","unstructured":"Sangar VK, McBain CA, Lyons J, Ramani VA, Logue JP, Wylie JP, et al. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys. 2005;61:420\u20135.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3400_CR31","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.eururo.2009.12.002","volume":"57","author":"VAC Ramani","year":"2010","unstructured":"Ramani VAC, Maddineni SB, Grey BR, Clarke NW. Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis. Eur Urol. 2010;57:1058\u201363.","journal-title":"Eur Urol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03400-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03400-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03400-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T05:13:04Z","timestamp":1718341984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03400-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["3400"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03400-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"assertion":[{"value":"17 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research was approved by the Institutional Ethical Committee of The Affiliated Hospital, Sun Yat-sen University (No. [2021] 493). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was waived for this type of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}